BioCardia (BCDA) CEO adds 900 shares in open‑market stock purchases

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman bought additional company stock in two open‑market transactions. He purchased 600 shares of common stock on March 24, 2026 at an average price of $1.24 per share and 300 shares on March 25, 2026 at an average price of $1.22 per share.

Both trades were executed in multiple lots within disclosed price ranges, with reported prices reflecting weighted averages. Following these purchases, Altman directly owns 274,766 shares of BioCardia common stock.

Insider Trade Summary

Net Buyer: 900 shares ($1,110)

Net Buy 2 txns

Insider Altman Peter

Role President and CEO

Bought 900 shs ($1K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	300	$1.22	$366.00
Purchase	Common Stock	600	$1.24	$744.00

Holdings After Transaction: Common Stock — 274,766 shares (Direct)

Footnotes (1)

1. This transaction was executed in multiple trades ranging from $1.24 to $1.26 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price. This transaction was executed in multiple trades ranging from $1.19 to $1.25 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		P		600(1)	A	$1.24(1)	274,466	D
Common Stock	03/25/2026		P		300(2)	A	$1.22(2)	274,766	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $1.24 to $1.26 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

2. This transaction was executed in multiple trades ranging from $1.19 to $1.25 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did BioCardia (BCDA) report for its CEO?

BioCardia reported that President and CEO Peter Altman bought common stock in the open market. He completed two separate purchases in late March 2026, modestly increasing his direct ownership stake in the company’s shares according to the Form 4 disclosure.

How many BioCardia shares did CEO Peter Altman buy and on which dates?

Peter Altman bought a total of 900 BioCardia common shares. He purchased 600 shares on March 24, 2026 and 300 shares on March 25, 2026, as detailed in the Form 4 insider trading report filed with regulators.

At what prices did the BioCardia CEO purchase his BCDA shares?

The CEO’s BioCardia share purchases were made at low single‑digit prices. On March 24, 2026 he bought 600 shares at an average of $1.24, and on March 25, 2026 he bought 300 shares at an average of $1.22 per share.

How many BioCardia shares does the CEO own after these transactions?

After the reported insider purchases, Peter Altman directly owns 274,766 shares of BioCardia common stock. This figure reflects his holdings following the March 25, 2026 transaction and represents his updated direct ownership position disclosed on the Form 4 filing.

Were the BioCardia CEO’s share purchases executed in multiple trades?

Yes. Each reported transaction was executed in multiple trades within specified price ranges, and the disclosed prices are weighted averages. The filing notes the CEO will provide full trade‑level details, including share amounts at each price, upon request to the SEC, the issuer, or security holders.